Evidence map›Paper›PMID 26918397›Full record

ArticlePediatric pulmonology2016

Bronchopulmonary dysplasia impairs L-type amino acid transporter-1 expression in human and baboon lung.

Erik L Bao, Anastasiya Chystsiakova, Mulugu V Brahmajothi, Mary E Sunday, Elizabeth N Pavlisko, Michael F Wempe, Richard L Auten

Abstract read
In one paragraph

Article in Pediatric pulmonology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Observational
  3. Nonhuman Primates in Translational Research.Annual review of animal biosciences · 2022
    Review
  4. Article
  5. Metabolic reprogramming in the pathogenesis of chronic lung diseases, including BPD, COPD, and pulmonary fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2018
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Erik L BaoDepartment of Pediatrics, Duke University Medical Center, Durham, 27710, North Carolina.
Anastasiya ChystsiakovaDepartment of Pediatrics, Duke University Medical Center, Durham, 27710, North Carolina.
Mulugu V BrahmajothiDepartment of Pediatrics, Duke University Medical Center, Durham, 27710, North Carolina.
Mary E SundayDepartment of Pathology, Duke University Medical Center, Durham, North Carolina.
Elizabeth N PavliskoDepartment of Pathology, Duke University Medical Center, Durham, North Carolina.
Michael F WempeDepartment of Pharmaceutical Sciences, School of Pharmacy, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado.
Richard L AutenDepartment of Pediatrics, Duke University Medical Center, Durham, 27710, North Carolina. richard.auten@conehealth.com.
Duke Medical Center · USDuke University Hospital · USUniversity of Colorado Denver · US

Funding

The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
NEUROPEPTIDES IN LUNG DEVELOPMENT AND INJURYU01HL052638 · NHLBI · DUKE UNIVERSITY · PI SUNDAY, MARY E. · 1999 to 2006
$2.0M
NHLBI NIH HHS U01 HL052638NIH HHS P51 OD011133
6 · The paper itself

Abstract

Bronchopulmonary dysplasia (BPD) is an inflammatory lung disorder common in premature infants who undergo mechanical ventilation with supplemental oxygen. Inhaled nitric oxide (iNO) has been used to prevent experimental and clinical BPD. Earlier studies showed that NO effects in alveolar epithelial cells (AEC) are mediated by S-nitrosothiol uptake via L-type amino acid transporter-1 (LAT1). Because LAT1 expression could influence the efficacy of iNO therapy, we sought to determine whether pulmonary LAT1 expression is altered in preterm baboons with experimental BPD and in human newborns susceptible to developing BPD. Using fixed lung obtained from 125 d to 140 d gestation baboon models of BPD, LAT1 immunostaining was measured in control and BPD animals. In adult controls and in 140 d gestational controls (GC), LAT1 was expressed in both type I and type II AECs. In 140 d BPD lungs, LAT1 expression density in alveolar tissue was decreased. In 125 d GC baboons, LAT1 immunostaining was largely confined to cuboidal AECs, whereas animals given 14 d of mechanical ventilation exhibited diminished alveolar septal LAT1 Labeling. The pattern in adult human donor lung was comparable to that observed in adult baboons. LAT1 was expressed in lungs obtained from some but not all very premature newborns at autopsy. In human and baboon lung, adult and newborn, pulmonary vascular cells expressed LAT1. In summary, LAT1 is expressed in AECs and pulmonary vascular cells in baboons and humans. Experimental BPD in premature baboons decreases pulmonary LAT1 expression and alters its spatial localization. Heterogeneity of functional LAT1 could affect S-nitrosothiol importation, which could impair iNO therapy. Pediatr Pulmonol. 2016;51:1048-1056. © 2016 Wiley Periodicals, Inc.

Indexed as

AdultAnimalsBronchopulmonary DysplasiaHumansInfant, NewbornInfant, PrematureInfant, Very Low Birth WeightLarge Neutral Amino Acid-Transporter 1LungNitric OxideOxygenPapioRespiration, ArtificialLarge Neutral Amino Acid-Transporter 1Nitric OxideOxygenlung diseasesneonatologypulmonary medicine

Identifiers

PMID26918397
PMCPMC5814304
OpenAlexW2279901239

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.